Oral chemotherapy for second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer

BACKGROUND: There is no standard therapy for second-line treatment of gemcitabine-refractory pancreatic cancer patients with poor performance status. A combination of chemotherapy drugs 5-fluorouracil (5-FU), leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) or 5-fluorouracil/leucovorin plus nano...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Se Jun, Kim, Hyunho, Shin, Kabsoo, Lee, Myung Ah, Hong, Tae Ho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2019
Materias:
Retrospective Cohort Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6883178/
https://www.ncbi.nlm.nih.gov/pubmed/31798782
http://dx.doi.org/10.4251/wjgo.v11.i11.1021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6883178/
https://www.ncbi.nlm.nih.gov/pubmed/31798782
http://dx.doi.org/10.4251/wjgo.v11.i11.1021

Ejemplares similares